troglitazone has been researched along with Glucose Intolerance in 17 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.
Excerpt | Relevance | Reference |
---|---|---|
"The primary purpose of this study was to assess the effects of 12 weeks of treatment with either troglitazone, an investigational thiazolidinedione that acts as an insulin-action enhancer, or placebo in patients with impaired glucose tolerance (IGT)." | 9.08 | Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. ( Antonucci, T; Lockwood, D; McLain, R; Norris, RM; Whitcomb, R, 1997) |
" Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus." | 8.80 | Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998) |
" Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 7.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
" Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12)." | 5.09 | Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000) |
"We conducted a randomized placebo-controlled study to determine the effects of the thiazolidinedione compound troglitazone on whole-body insulin sensitivity (SI), pancreatic beta-cell function, and glucose tolerance in 42 Latino women with impaired glucose tolerance (IGT) and a history of gestational diabetes mellitus (GDM), characteristics that carry an 80% risk of developing NIDDM within 5 years." | 5.08 | Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. ( Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A, 1996) |
"The primary purpose of this study was to assess the effects of 12 weeks of treatment with either troglitazone, an investigational thiazolidinedione that acts as an insulin-action enhancer, or placebo in patients with impaired glucose tolerance (IGT)." | 5.08 | Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. ( Antonucci, T; Lockwood, D; McLain, R; Norris, RM; Whitcomb, R, 1997) |
" Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus." | 4.80 | Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998) |
" Metformin, an antihyperglycemic drug of the biguanide class, may be effective in subjects with IGT by reducing hepatic glucose output, enhancing insulin sensitivity, or through other mechanisms such as weight loss." | 4.79 | [Drug therapy in subjects with impaired glucose tolerance]. ( Kawamori, R; Yoshii, H, 1996) |
" The occult diabetic group had an abnormal response to hyperemia before the treatment with troglitazone and showed little change in flow after BA occlusion." | 3.70 | Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. ( Avena, R; Curry, KM; Mitchell, ME; Nylen, ES; Sidawy, AN, 1998) |
" Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 3.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
" The objective of this study was to examine the impact of chronic use of an insulin sensitizer on glucose metabolism in normal glucose tolerant AA at risk for DM (previous gestational diabetes mellitus [GDM] or first-degree relative with DM)." | 2.71 | The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study. ( Gaillard, T; Habash, D; Osei, K; Rhinesmith, S; Schuster, D, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (58.82) | 18.2507 |
2000's | 7 (41.18) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Pugeat, M | 1 |
Schuster, D | 1 |
Gaillard, T | 1 |
Rhinesmith, S | 1 |
Habash, D | 1 |
Osei, K | 1 |
Schröder, AK | 1 |
Tauchert, S | 1 |
Ortmann, O | 1 |
Diedrich, K | 1 |
Weiss, JM | 1 |
Xiang, AH | 2 |
Peters, RK | 2 |
Kjos, SL | 3 |
Goico, J | 3 |
Ochoa, C | 2 |
Marroquin, A | 3 |
Tan, S | 1 |
Hodis, HN | 1 |
Azen, SP | 2 |
Buchanan, TA | 3 |
Ehrmann, DA | 2 |
Berkowitz, K | 2 |
Peters, R | 1 |
Dunn, ME | 1 |
Xiang, A | 1 |
Azen, S | 1 |
Henry, RR | 1 |
Kawamori, R | 1 |
Yoshii, H | 1 |
Antonucci, T | 1 |
Whitcomb, R | 1 |
McLain, R | 1 |
Lockwood, D | 1 |
Norris, RM | 1 |
Cavaghan, MK | 1 |
Byrne, MM | 1 |
Polonsky, KS | 1 |
Linday, LA | 1 |
Yoshioka, K | 2 |
Yokoo, S | 1 |
Yoshida, T | 1 |
Kondo, M | 1 |
Johnson, MD | 1 |
Campbell, LK | 1 |
Campbell, RK | 1 |
Avena, R | 1 |
Mitchell, ME | 1 |
Nylen, ES | 1 |
Curry, KM | 1 |
Sidawy, AN | 1 |
Yamakita, T | 1 |
Ishii, T | 1 |
Mori, T | 1 |
Sato, T | 1 |
Tanaka, S | 1 |
Kurimasa, H | 1 |
Fujita, K | 1 |
Fujii, S | 1 |
Nakamura, T | 1 |
Funahashi, T | 1 |
Yamashita, S | 1 |
Nishida, M | 1 |
Nishida, Y | 1 |
Takahashi, M | 1 |
Hotta, K | 1 |
Kuriyama, H | 1 |
Kihara, S | 1 |
Ohuchi, N | 1 |
Nishimura, T | 1 |
Kishino, BI | 1 |
Ishikawa, K | 1 |
Kawamoto, T | 1 |
Tokunaga, K | 1 |
Nakagawa, C | 1 |
Mineo, I | 1 |
Watanabe, F | 1 |
Tarui, S | 1 |
Matsuzawa, Y | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272] | 128 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918] | 60 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471] | 36 participants (Anticipated) | Observational | 2012-12-06 | Active, not recruiting | |||
The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes[NCT00194896] | 64 participants (Actual) | Interventional | 2000-02-29 | Completed | |||
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
Effect of Gain on Closed-Loop Insulin[NCT02065895] | 8 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Number of participants positive for T cell reactivity to islet proteins at 36 months. (NCT00194896)
Timeframe: 36 months
Intervention | participants (Number) |
---|---|
Rosiglitazone Autoantibody Positive | 1 |
Rosiglitazone Autoantibody Negative | 2 |
Glyburide Autoantibody Positive | 2 |
Glyburide Autoantibody Negative | 3 |
Changes in beta cell function assessed by fasting and stimulated C-peptide measured at 36 months. (NCT00194896)
Timeframe: 36 months
Intervention | ng per ml (Mean) | |
---|---|---|
Fasting C-peptide | Glucagon Stimulated C-peptide | |
Glyburide Autoantibody Negative | 0.3 | 0.3 |
Glyburide Autoantibody Positive | 0.1 | 3.1 |
Rosiglitazone Autoantibody Negative | -1.4 | -2.8 |
Rosiglitazone Autoantibody Positive | -0.4 | -0.6 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | mmol/l (Mean) | |
---|---|---|
Baseline FSG | 3rd Month FSG | |
Metformin ( 002 Group) | 6.2 | 6.5 |
Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | μU/ml (Mean) | |
---|---|---|
Baseline FSI | 3rd month FSI | |
Metformin ( 002 Group) | 13.0 | 13.9 |
Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
Intervention | percentage (Mean) | |
---|---|---|
Baseline HbA1c | 3rd month HbA1c | |
Metformin ( 002 Group) | 7.8 | 7.0 |
Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | percentage (Mean) | |||
---|---|---|---|---|
Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | Score on a scale ( SI unit) (Mean) | |||
---|---|---|---|---|
Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
Intervention | mg/dl (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
Glucose Area Under the Curve (AUC) Breakfast defines the total exposure to glucose during breakfast. Breakfast is typically considered the most difficult meal to control; low AUC is desirable.This outcome measure was analyzed for each of the three calibration error values (high error, no error and low error). (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 2:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
Intervention | mmol/l/min (Mean) |
---|---|
HIGH Error | 66.8 |
NO Error | 48.8 |
LOW Error | 37.4 |
Night-time in target range 5.0-8.33, following the 3 hour controller initialization period blood glucose remained at or near target. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 12:00 AM to 6:00 AM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
Intervention | percentage of time in target range (Median) |
---|---|
HIGH Error | 88 |
NO Errror | 100 |
LOW Error | 80 |
Highest and lowest glucose concentrations obtained during breakfast meal. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 12:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
Intervention | mmol/l (Mean) | |
---|---|---|
Peak glucose concentration | Nadir glucose concentration | |
Gain Decreased and Target Increased | 11.3 | 6.6 |
Gain Increased and Target Decreased | 13.3 | 4.5 |
Nadir Mean | 11.8 | 4.8 |
6 reviews available for troglitazone and Glucose Intolerance
Article | Year |
---|---|
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem | 2003 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Effects of troglitazone on insulin sensitivity.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Gl | 1996 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase | 1996 |
Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Topics: Animals; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Glucose Intolerance; Humans; Hypogly | 1998 |
8 trials available for troglitazone and Glucose Intolerance
Article | Year |
---|---|
The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
Topics: Adult; Black People; Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Chromans; Diabete | 2003 |
Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Hispanic or | 2004 |
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LD | 1996 |
Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Chromans; Double-Blind Method; Ethnicity; Glucose Intolerance | 1997 |
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
Topics: Administration, Oral; Adult; Animals; Chromans; Double-Blind Method; Female; Glucose; Glucose Intole | 1997 |
Trivalent chromium and the diabetes prevention program.
Topics: Chromans; Chromium; Clinical Protocols; Complementary Therapies; Diabetes Mellitus, Type 2; Diet; Ex | 1997 |
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolera | 2000 |
Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial.
Topics: Adipose Tissue; Blood Glucose; Blood Pressure; Body Composition; Cholesterol; Chromans; Double-Blind | 2001 |
3 other studies available for troglitazone and Glucose Intolerance
Article | Year |
---|---|
Is troglitazone a real indication for obese subjects with impaired glucose tolerance?
Topics: Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Obesity; Thia | 1997 |
Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.
Topics: Aged; Blood Flow Velocity; Brachial Artery; Chromans; Fasting; Glucose Intolerance; Glucose Toleranc | 1998 |
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intoleran | 1998 |